An official website of the United States government
Home
Name
Filgrastim
Alternate Names
G-CSF
GCSF
Neupogen
Recombinant human granulocyte colony-stimulating factor
Zarxio
r-G-CSF
r-met Hu G-CSF
rhG-CSF
Abbreviations
None
Category
Ancillary Agent
Subcategory
None
NSC Number
614371
614629
Primary Site
None
Histology
None
Remarks
A granulocyte colony-stimulating factor (G-CSF). Adjunct of Ganciclovir therapy; treatment of neutropenia
March 2015: Zarxio is the first biosimilar product approved in the United States. A biosimilar product is a biological product that is based on a showing that it is highly similar to an already-approved biological product, known as a reference product. There are no differences in terms of safety and effectiveness from the reference product (neupogen)
March 2015: Zarxio is the first biosimilar product approved in the United States. A biosimilar product is a biological product that is based on a showing that it is highly similar to an already-approved biological product, known as a reference product. There are no differences in terms of safety and effectiveness from the reference product (neupogen)
Coding
This drug should NOT be coded
